The question bank is the fastest way to start, but PMHNP Helper also includes board-review planning, student resources, and plain-English guidance for psychiatric nurse practitioner students who are still learning the exam landscape.
advancedvalproic acidtherapeutic drug monitoringketogenic dietprotein bindingfree drug levelsbipolar disorderpharmacokinetics
A 42-year-old male with bipolar I disorder has been maintained on valproic acid 1500 mg daily for two years with good mood stability. He presents for routine monitoring and reports no mood symptoms. His most recent valproic acid trough level is 62 mcg/mL, drawn appropriately at 12 hours post-dose. Three months ago, his level was 85 mcg/mL on the same dose. He denies any medication changes, missed doses, or new medications. He reports he recently started a high-protein, low-carbohydrate ketogenic diet six weeks ago for weight loss and has lost 14 pounds. His AST and ALT are mildly elevated at 48 and 52 U/L respectively, up from baseline values of 28 and 30 U/L. Serum albumin is 4.2 g/dL, ammonia is 42 mcmol/L, and CBC with platelets is within normal limits. The PMHNP is evaluating the significance of the decreased valproic acid level and hepatic enzyme changes. Which of the following best represents the appropriate evaluation?
Explanation
The ketogenic diet produces elevated circulating free fatty acids that compete with valproic acid for albumin binding sites, increasing the free drug fraction while decreasing total measured serum levels. Evaluating only total valproic acid levels in this context can be misleading and may prompt inappropriate dose increases that result in toxicity from elevated free drug concentrations.
Key Takeaway
When a patient on valproic acid starts a ketogenic diet, declining total drug levels may reflect protein binding displacement by free fatty acids rather than true subtherapeutic exposure, and a free valproic acid level should be obtained before adjusting the dose.